Oragenics Inc. (NYSE American: OGEN) announced that all three sites in its Australian Phase IIa clinical trial of ONP-002 for mild traumatic brain injury (concussion) are now active and enrolling participants, following the activation of Royal Adelaide Hospital. The company reported that no serious adverse events have been observed in dosed participants to date and continues to target a Phase IIa data readout in the fourth quarter of 2026.
In addition to the trial progress, Oragenics submitted a Type B meeting request to the U.S. Food and Drug Administration on June 26 to obtain guidance on its planned U.S. clinical development program for ONP-002. The company noted that this meeting supports its goal of submitting an Investigational New Drug application in the fourth quarter of 2026. The full press release is available at https://ibn.fm/Yye2E.
Oragenics is a clinical-stage biotechnology company focused on developing brain-targeted therapeutics through proprietary intranasal delivery technology. Its lead candidate, ONP-002, is being investigated as a potential first-in-class treatment for concussion and mild traumatic brain injury. The company is currently conducting clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. More information is available at oragenics.com.
The activation of all trial sites marks a significant milestone for Oragenics as it progresses toward a potential new treatment for concussion, a condition with limited therapeutic options. The company's intranasal delivery platform may have broader applications across neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders. Investors and stakeholders can find the latest news and updates at https://ibn.fm/OGEN.
